{"": [211, 1288, 0], "1. Introduction": [1289, 6948, 0], "2.1. Vaccination of Mice and SARS-CoV-2 Challenge": [6975, 8808, 0], "2.2. Human Convalescent Sera": [8809, 9235, 0], "2.3. Neutralizing Titer Assay": [9236, 10887, 0], "2.4. RBD-Directed Antibody ELISA": [10888, 14383, 0], "2.5. Histopathology and Immunohistochemistry": [14384, 16284, 0], "2.6. TCID50 Assays": [16285, 17247, 0], "2.7. Cytokine Analysis": [17248, 18304, 0], "2.8. Statistical Analysis": [18305, 18684, 0], "2. Materials and Methods": [6949, 18684, 1], "3.1. K18-hACE2 Mice Exhibit an Antibody Response to CoV-RBD121-NP Vaccination That Resembles the Response in Serum from Convalescent Human COVID-19 Patients": [18697, 21460, 0], "3.2. K18-hACE2 Mice Are Protected from SARS-CoV-2-Induced Disease and Mortality by CoV-RBD121-NP Vaccination": [21461, 25648, 0], "3.3. Either Dosing Regimen of CoV-RBD121-NP Vaccination Reduces Immune Cell Accumulation in K18-hACE2 Mice Challenged with SARS-CoV-2": [25649, 27267, 0], "3.4. Increased CXCL5 Is Correlated with Protection from SARS-CoV-2-Induced Disease and Mortality in K18-hACE2 Mice ": [27268, 29988, 0], "3. Results": [18685, 29988, 1], "4. Discussion": [29989, 39586, 0]}